# A Study to Evaluate the Efficacy and Safety of Oral Navelbine in Female Patients With HER2-Negative Metastatic Breast Cancer

> **NCT03854617** · PHASE2 · UNKNOWN · sponsor: **Chinese Academy of Medical Sciences** · enrollment: 172 (estimated)

## Conditions studied

- Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

## Interventions

- **DRUG:** Oral NVB Metronomic
- **DRUG:** Oral NVB Weekly

## Key facts

- **NCT ID:** NCT03854617
- **Lead sponsor:** Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-02-20
- **Primary completion:** 2021-12-20
- **Final completion:** 2025-12-20
- **Target enrollment:** 172 (ESTIMATED)
- **Last updated:** 2019-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03854617

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03854617, "A Study to Evaluate the Efficacy and Safety of Oral Navelbine in Female Patients With HER2-Negative Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03854617. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*